Your shopping cart is currently empty

γ-Fibrinogen377-395 is a peptide derived from fibrinogen, functioning both as an inhibitory molecule and an epitope. It inhibits microglial activation, disrupts fibrin-Mac-1 interactions in vitro, and mitigates experimental autoimmune encephalomyelitis (EAE) in murine models in vivo. This compound is relevant for research into multiple sclerosis (MS) and other neuroinflammatory disorders characterized by blood-brain barrier compromise and microglial activation [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | γ-Fibrinogen377-395 is a peptide derived from fibrinogen, functioning both as an inhibitory molecule and an epitope. It inhibits microglial activation, disrupts fibrin-Mac-1 interactions in vitro, and mitigates experimental autoimmune encephalomyelitis (EAE) in murine models in vivo. This compound is relevant for research into multiple sclerosis (MS) and other neuroinflammatory disorders characterized by blood-brain barrier compromise and microglial activation [1]. |
| In vitro | The compound γ-Fibrinogen377-395 at a concentration of 200 μM inhibits the binding of fibrinogen to Mac-1, thereby reducing the adhesion of Mac-1 overexpressing cells to immobilized fibrinogen. Additionally, γ-Fibrinogen377-395 suppresses the activation of microglia [1]. |
| In vivo | γ-Fibrinogen377-395 (30 μg/mouse; intranasal administration; once daily for 40 days) improved motor function in mice without affecting peripheral immune responses or altering coagulation properties. Additionally, mice immunized with γ377-395 peptide before EAE induction showed enhanced motor strength and coordination compared to the control group [1]. |
| Molecular Weight | 2229.66 |
| Formula | C100H165N25O28S2 |
| Cas No. | 957792-67-5 |
| Smiles | C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CC=C(O)C=C1)N)=O)CO)=O)CCSC)=O)CCCCN)=O)CCC(O)=O)=O)[C@@H](C)O)=O)[C@@H](C)O)=O)CCSC)=O)CCCCN)=O)[C@H](CC)C)=O)[C@H](CC)C)(=O)N2[C@H](C(N[C@@H](CC3=CC=CC=C3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(O)=O)=O)[C@H](CC)C)=O)CO)=O)CC(C)C)=O)CCCNC(=N)N)=O)CC(N)=O)=O)=O)CCC2 |
| Sequence | Tyr-Ser-Met-Lys-Glu-Thr-Thr-Met-Lys-Ile-Ile-Pro-Phe-Asn-Arg-Leu-Ser-Ile-Gly |
| Sequence Short | YSMKETTMKIIPFNRLSIG |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.